Progress in strategies aimed at breaking down therapeutic target proteins has led to a
paradigm shift in drug discovery. Thalidomide and its derivatives are the only protein …

Large conductance Ca 2+-and voltage-activated K+(BK) channels are widely distributed in
the postnatal central nervous system (CNS). BK channels play a pleiotropic role in …

KCNMA1 encodes the pore-forming α subunit of the “Big K+”(BK) large conductance calcium
and voltage-activated K+ channel. BK channels are widely distributed across tissues …

Large-conductance Ca 2+-activated K+ channels facilitate the efflux of K+ ions from a variety
of cells and tissues following channel activation. It is now recognized that BK channels …

Thalidomide was sold worldwide as a sedative over 60 years ago, but it was quickly
withdrawn from the market due to its teratogenic effects. Thalidomide was later found to have …

Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically
effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide …

The resting membrane potential (Δψ) of the cell is negative on the cytosolic side and
determined primarily by the plasma membrane's selective permeability to K+. We show that …

Proteolysis-targeting chimeras (PROTACs) bring a protein of interest (POI) into spatial
proximity of an E3 ubiquitin ligase, promoting POI ubiquitylation and proteasomal …

Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was
identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is …

Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon
(CRBN) and activate the CRL4CRBN ubiquitin ligase to trigger proteasomal degradation of …